目的: 分析皮层蛋白Cortactin在肿瘤组织的表达水平和肿瘤出芽程度与结肠直肠癌特征的相关关系。方法: 检测97例结肠直肠癌病人癌组织Cortactin的表达水平和肿瘤出芽程度,分析其与病人临床特征的相关性。结果: Cortactin表达水平与结肠直肠癌病人T分期（P=0.017）和N分期（P<0.001）显著相关。结肠直肠癌Cortactin表达水平较高的病人年龄较小（P=0.043）。肿瘤出芽程度与病人T分期（P=0.031）、血浆CEA水平（P=0.038）以及结肠直肠癌高危因素（P=0.008）显著相关。Cortactin表达与结肠直肠癌肿瘤出芽程度显著相关（P=0.011）。结论: Cortactin表达水平与结肠直肠癌出芽显著相关,提示Cortactin可能促进结肠直肠癌细胞出芽、恶性进展和预后不良。
Objective To evaluate Cortactin expression level in the patients with colorectal cancer(CRC) and tumor budding related with the clinical characteristics. Methods The expression of Cortactin and tumor budding levels were detected in 97 CRC patients and the correlations of Cortactin and tumor budding with clinical characteristics were determined. Results Cortactin expression level was significantly related with T stage(P=0.017) and N stage(P<; 0.001) of CRC patients. The patients with higher Cortactin expression level were younger than those with lower Cortactin expression (P=0.043). The tumor budding level was significantly related with T stage (P=0.031), plasma CEA level (P=0.038) and the risk factors of CRC (P=0.008). There was relationship between Cortactin level and tumor budding level in patients with CRC(P=0.011). Conclusions Cortactin expression would be related significantly with the tumor budding of CRC patients. Higher expression of Cortactin suggests the patients poorer prognostic by the mechanism that Cortactin promotes tumor budding and progression of CRC.
[1] van Wyk HC, Park JH, Edwards J, et al. The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer[J]. Br J Cancer,2016,115(2):156-163.
[2] Wu H, Reynolds AB, Kanner SB, et al.Identification and characterization of a novel cytoskeleton-associated pp60src substrate[J]. Mol Cell Biol,1991,11(10):5113-5124.
[3] Cai JH, Zhao R, Zhu JW, et al.Expression of cortactin correlates with a poor prognosis in patients with stages Ⅱ-Ⅲ colorectal adenocarcinoma[J]. J Gastrointest Surg,2010,14(8):1248-1257.
[4] 朱建伟, 陆毅样, 赵任, 等. 皮层蛋白氨基端同源性多肽分子对大肠癌细胞迁移、内吞能力及侵袭性的抑制[J]. 世界华人消化杂志,2009,17(32):3302-3306.
[5] Edge SB, Byrd DR, Compton CC, et al.AJCC Cancer staging manual[M]. 7th ed. New York:Springer,2010.
[6] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[7] Wang R, Wang MJ, Ping J.Clinicopathological features and survival outcomes of colorectal cancer in young versus elderly: A population-based cohort study of SEER 9 registries data(1988-2011)[J]. Medicine (Baltimore),2015,94(35):e1402.
[8] Graham RP, Vierkant RA, Tillmans LS, et al.Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort[J]. Am J Surg Pathol,2015,39(10):1340-1346.
[9] Caie PD, Turnbull AK, Farrington SM, et al.Quantification of tumour budding, lymphatic vessel density and invasion through image analysis in colorectal cancer[J]. J Transl Med,2014,12:156-168.
[10] Shinto E, Mochizuki H, Ueno H, et al.A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci[J]. Histopathology,2005,47(1):25-31.
[11] Shinto E, Mochizuki H, Ueno H, et al.A novel classification of tumour budding in colorectal cancer based on the presence of cytoplasmic pseudo-fragments around budding foci[J]. Histopathology,2005,47(1):25-31.
[12] Pollard TD, Borisy GG.Cellular motility driven by assembly and disassembly of actin filaments[J]. Cell,2003, 112(4):453-465.
[13] Bryce NS, Clark ES, Leysath JL, et al.Cortactin promotes cell motility by enhancing lamellipodial persistence[J]. Curr Biol,2005,15(14):1276-1285.
[14] Mueller SC, Yeh Y, Chen WT.Tyrosine phosphorylation of membrane proteins mediates cellular invasion by transformed cells[J]. J Cell Biol,1992,119(5):1309-1325.
[15] Mizutani K, Miki H, He H, et al.Essential role of neural Wiskott-Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src-transformed fibroblasts[J]. Cancer Res,2002,62(3):669-674.
[16] Zhang X, Liu K, Zhang T, et al.Cortactin promotes co-lorectal cancer cell proliferation by activating the EGFR-MAPK pathway[J]. Oncotarget,2017,8(1):1541-1554.
[17] Prall F, Nizze H, Barten M.Tumour budding as prognostic factor in stage Ⅰ/Ⅱ colorectal carcinoma[J]. Histopa-thology,2005,47(1):17-24.
[18] Prall F, Weirich V, Ostwald C.Phenotypes of invasion in sporadic colorectal carcinomas related to aberrations of the adenomatous polyposis coli (APC) gene[J]. Histopa-thology,2007,50(3):318-330.
[19] Jass JR, Barker M, Fraser L, et al.APC mutation and tumour budding in colorectal cancer[J]. J Clin Pathol,2003,56(1):69-73.
[20] Garcia-Solano J, Conesa-Zamora P, Trujillo-Santos J, et al.Immunohistochemical expression profile of β-catenin, E-cadherin, P-cadherin, laminin-5γ2 chain, and SMAD4 in colorectal serrated adenocarcinoma[J]. Hum Pathol,2012,43(7):1094-102.
[21] Brabletz T, Hlubek F, Spaderna S, et al.Invasion and metastasis in colorectal cancer: epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin[J]. Cells Tissues Organs,2005,179(1-2):56-65.
[22] Markl B, Hardt J, Franz S, et al.Tumor budding, uPA, and PAI-1 in colorectal cancer: update of a prospective study[J]. Gastroenterol Res Pract,2017,2017:6504960.
